Ryan Haumschild, PharmD, MS, MBA from Pharmacy Times - Journalist Profile

	Profile	Recent Articles on Subject
1	Frank Scimeca, PharmD, MBA, BCOP Pharmacy Times	Bridging the Gap: Multidisciplinary Collaboration in Early Breast Cancer Care - 5 months ago Navigating Therapy Approval for Early Breast Cancer: An Operational Perspective - 5 months ago Alternative Treatments for eBC and mBC - 5 months ago Balancing Clinical and Economic Factors in Early Breast Cancer Treatment - 5 months ago
2	Britny Brown, PharmD, BCOP Pharmacy Times	Bridging the Gap: Multidisciplinary Collaboration in Early Breast Cancer Care - 5 months ago Navigating Therapy Approval for Early Breast Cancer: An Operational Perspective - 5 months ago Alternative Treatments for eBC and mBC - 5 months ago Balancing Clinical and Economic Factors in Early Breast Cancer Treatment - 5 months ago
3	Heather Moore, BCOP, CPP, PharmD Pharmacy Times	Bridging the Gap: Multidisciplinary Collaboration in Early Breast Cancer Care - 5 months ago Navigating Therapy Approval for Early Breast Cancer: An Operational Perspective - 5 months ago Alternative Treatments for eBC and mBC - 5 months ago Balancing Clinical and Economic Factors in Early Breast Cancer Treatment - 5 months ago
4	Ryan Haumschild, PharmD, MS, MBA Pharmacy Times Director of Pharmacy. Editorial Board member. Atlanta, Georgia pharmacyhealthcareeditorial workadvisory	Bridging the Gap: Multidisciplinary Collaboration in Early Breast Cancer Care - 5 months ago Navigating Therapy Approval for Early Breast Cancer: An Operational Perspective - 5 months ago Alternative Treatments for eBC and mBC - 5 months ago Balancing Clinical and Economic Factors in Early Breast Cancer Treatment - 5 months ago Team Approach to Meeting REMS Program Requirements - 6 months ago Considerations for Maintenance Therapy in the Community Oncology Setting - 6 months ago Key Points of Emphasis Surrounding CDK4/6 Inhibitor in mBC Treatment - 12 months ago Unmet Needs in mBC Treatment Landscape - 12 months ago Navigating Medication Therapy Management in mBC Treatment - about 1 year ago NCCN Guidelines on CDK4/6 Inhibitor Treatment Regimens - about 1 year ago Differentiating Between Adverse Event Profiles of Various CDK4/6 Inhibitors - about 1 year ago Progression-Free Survival and Overall Survival Associated With CDK4/6 Inhibitor Therapy - about 1 year ago Hormone Therapy in Patients with HR+/HER2- Metastatic Breast Cancer - about 1 year ago Experts Discuss Oncology Drug Shortages, Patient Access in Oncology - about 1 year ago
5	Sarah Rockwell, PharmD, BCOP Pharmacy Times	Team Approach to Meeting REMS Program Requirements - 6 months ago Considerations for Maintenance Therapy in the Community Oncology Setting - 6 months ago
6	Ke Ning, MD Pharmacy Times	Team Approach to Meeting REMS Program Requirements - 6 months ago Considerations for Maintenance Therapy in the Community Oncology Setting - 6 months ago
7	Heather Moore, CPP, PharmD, BCOP Pharmacy Times Oncology Pharmacist. Exercise Enthusiast. Animal Lover. Durham, North Carolina PharmacyOncologyFitness	Key Points of Emphasis Surrounding CDK4/6 Inhibitor in mBC Treatment - 12 months ago Navigating Medication Therapy Management in mBC Treatment - about 1 year ago Progression-Free Survival and Overall Survival Associated With CDK4/6 Inhibitor Therapy - about 1 year ago
8	Jacob K. Kettle, PharmD, BCOP Pharmacy Times #pharmacy news, insights. CE provider. Cranbury, New Jersey pharmacyhealthcarejournalism	Key Points of Emphasis Surrounding CDK4/6 Inhibitor in mBC Treatment - 12 months ago Unmet Needs in mBC Treatment Landscape - 12 months ago Navigating Medication Therapy Management in mBC Treatment - about 1 year ago NCCN Guidelines on CDK4/6 Inhibitor Treatment Regimens - about 1 year ago
9	Rose DiMarco, PharmD, BCPS, BCOP Pharmacy Times Dedicated journal for oncology practitioners. Huntington, New York oncologyhealthcare	Key Points of Emphasis Surrounding CDK4/6 Inhibitor in mBC Treatment - 12 months ago Progression-Free Survival and Overall Survival Associated With CDK4/6 Inhibitor Therapy - about 1 year ago Hormone Therapy in Patients with HR+/HER2- Metastatic Breast Cancer - about 1 year ago
10	Heather Moore, PharmD, CPP, BCOP Pharmacy Times	Differentiating Between Adverse Event Profiles of Various CDK4/6 Inhibitors - about 1 year ago